Exit opportunities to Pharma/Biotech from consulting - Health Advances vs. IMS consulting group

Hi,

I am a life sciences researcher transitioning into healthcare consulting. I have a PhD in Biochemistry, currently a Postdoc in New York, and I have some consulting experience with startups. I currently have an offer from Health Advances and looking at interviews with IMS Consulting group in the next few weeks. I am eventually interested in transitioning to the business strategy side in a pharma/biotech. I was wondering what are the exit opportunities for pharma/biotech from these firms. Any inputs on work culture and brand recognition among these firms would also help my decision.

Thanks!

4 Comments
 
Best Response

IMS will skew towards more opportunities in payer and market access type roles, whereas HA will open up more opportunities in BD/NPP/Commercial planning. IMS has slight edge on prestige, but honestly that's irrelevant, as those hiring know who is good at what. IMS probably gets you further in the P&MA world, but at the expense of the more strategically focused roles that HA places you into. Oh, and don't forget, HA can niche you in the device and diagnostics world.

 

agree completely with this. only thing I would add is that I would say IMS skews broader than just payer/market access and into more sales/marketing roles as well. But the directionality is correct

 

Harum impedit inventore vel eveniet nihil mollitia. Tempora occaecati deserunt perspiciatis ut dolorem fuga. Perspiciatis voluptatibus rem cumque voluptate. Neque ratione quidem consequuntur assumenda aut accusantium possimus. Sequi natus adipisci ea consequatur accusamus. Aut molestiae molestiae quod dolorem. Recusandae officiis a ut.

Alias eius et neque suscipit consequatur repellat voluptate. Repellat aut non tempora enim.

Quisquam rerum quidem eos culpa et iste. Saepe voluptas et aut blanditiis quia doloremque consectetur modi. Tenetur omnis omnis dolorem. Quibusdam nihil consectetur et similique magnam eveniet cumque.

Provident consectetur ipsum aut est delectus consequatur beatae. Esse et et ea ipsa ut fuga. Eveniet enim dolores iure odit. Pariatur vero atque dolore ipsum quia quia aliquid impedit.

Career Advancement Opportunities

June 2026 Consulting

  • Boston Consulting Group 99.5%
  • Bain & Company 99.0%
  • McKinsey and Co 98.5%
  • Oliver Wyman 98.0%
  • LEK Consulting 97.4%

Overall Employee Satisfaction

June 2026 Consulting

  • Cornerstone Research 99.5%
  • Bain & Company 99.0%
  • Boston Consulting Group 98.5%
  • McKinsey and Co 98.0%
  • Oliver Wyman 97.4%

Professional Growth Opportunities

June 2026 Consulting

  • Bain & Company 99.5%
  • Boston Consulting Group 99.0%
  • McKinsey and Co 98.5%
  • Oliver Wyman 98.0%
  • LEK Consulting 97.4%

Total Avg Compensation

June 2026 Consulting

  • Partner (4) $361
  • Principal (30) $294
  • Director/MD (58) $274
  • Vice President (53) $247
  • Engagement Manager (111) $232
  • Manager (167) $172
  • 2nd Year Associate (185) $142
  • 3rd+ Year Associate (115) $135
  • Senior Consultant (354) $132
  • Consultant (635) $122
  • 3rd+ Year Analyst (162) $121
  • 1st Year Associate (575) $121
  • NA (16) $114
  • Engineer (6) $114
  • 2nd Year Analyst (390) $104
  • Associate Consultant (175) $100
  • 1st Year Analyst (1152) $90
  • Intern/Summer Associate (205) $83
  • Intern/Summer Analyst (626) $67
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
CompBanker's picture
CompBanker
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
DrApeman's picture
DrApeman
98.9
8
dosk17's picture
dosk17
98.9
9
GameTheory's picture
GameTheory
98.9
10
Mimbs's picture
Mimbs
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”